Literature DB >> 33611582

Mid-term outcomes of coronary artery bypass grafting in patients with mild left ventricular systolic dysfunction: a multicentre retrospective cohort study.

Hang Zhang1, Ronghui Shi2, Wei Qin1, Wen Chen1, Liangpeng Li1, Wuwei Wang1, Yang Zhao3, Rui Wang1, Xin Chen1.   

Abstract

OBJECTIVES: Left ventricular systolic dysfunction (LVSD) is common and associated with adverse events in patients receiving coronary artery bypass grafting (CABG). However, the prognosis of mild LVSD has not been clearly described. We aimed to evaluate the mid-term outcomes of patients with mild LVSD following CABG.
METHODS: This multicentre cohort study using propensity score matching took place from December 2012 to October 2019 in Jiangsu Province, China, with a mean and maximum follow-up of 3.2 and 7.2 years, respectively. Patients were classified to normal left ventricular systolic function (left ventricular ejection fraction ≥53%) and mild LVSD (left ventricular ejection fraction >40%/<53%). The primary outcomes were death from all causes and death from cardiovascular causes. The secondary outcomes were heart failure, myocardial infarction, repeat revascularization and a composite of all mentioned outcomes, including death from all causes (major adverse events).
RESULTS: A total of 581 pairs were formed after matching. In-hospital death (1.5% vs 2.1%, P = 0.51) did not differ between 2 cohorts. Throughout 7 years, mild LVSD was associated with higher rates of death from all causes [hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.39-0.89; P = 0.012], death from cardiovascular causes (HR 0.55, 95% CI 0.36-0.90; P = 0.017), heart failure (HR 0.60, 95% CI 0.37-0.93; P = 0.023) and major adverse events (HR 0.66, 95% CI 0.49-0.91; P = 0.009). There was no difference in the rates of myocardial infarction and repeat revascularization.
CONCLUSIONS: Mild LVSD was associated with a worse mid-term prognosis in patients following CABG.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Coronary artery bypass grafting; Left ventricular ejection fraction; Mild left ventricular systolic dysfunction; Prognosis

Mesh:

Year:  2021        PMID: 33611582      PMCID: PMC8691535          DOI: 10.1093/icvts/ivab005

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  20 in total

Review 1.  A Review of Propensity-Score Methods and Their Use in Cardiovascular Research.

Authors:  Saswata Deb; Peter C Austin; Jack V Tu; Dennis T Ko; C David Mazer; Alex Kiss; Stephen E Fremes
Journal:  Can J Cardiol       Date:  2015-05-23       Impact factor: 5.223

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

3.  Coronary Bypass--Survival Benefit in Heart Failure.

Authors:  Robert A Guyton; Andrew L Smith
Journal:  N Engl J Med       Date:  2016-04-03       Impact factor: 91.245

4.  A randomized trial of coronary artery bypass surgery. Survival of patients with a low ejection fraction.

Authors:  E Passamani; K B Davis; M J Gillespie; T Killip
Journal:  N Engl J Med       Date:  1985-06-27       Impact factor: 91.245

5.  Natural history of asymptomatic left ventricular systolic dysfunction in the community.

Authors:  Thomas J Wang; Jane C Evans; Emelia J Benjamin; Daniel Levy; Elizabeth C LeRoy; Ramachandran S Vasan
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

6.  Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%.

Authors:  Kun-Lun He; Daniel Burkhoff; Wen-Xiu Leng; Zhi-Ru Liang; Li Fan; Jie Wang; Mathew S Maurer
Journal:  Am J Cardiol       Date:  2009-03-15       Impact factor: 2.778

7.  Prognosis of Adults With Borderline Left Ventricular Ejection Fraction.

Authors:  Connie W Tsao; Asya Lyass; Martin G Larson; Susan Cheng; Carolyn S P Lam; Jayashri R Aragam; Emelia J Benjamin; Ramachandran S Vasan
Journal:  JACC Heart Fail       Date:  2016-06       Impact factor: 12.035

8.  Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions.

Authors:  Nancy K Sweitzer; Margarita Lopatin; Clyde W Yancy; Roger M Mills; Lynne W Stevenson
Journal:  Am J Cardiol       Date:  2008-02-20       Impact factor: 2.778

9.  Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis.

Authors:  Stephan Windecker; Stefan Stortecky; Giulio G Stefanini; Bruno R da Costa; Bruno R daCosta; Anne Wilhelmina Rutjes; Marcello Di Nisio; Maria G Silletta; Maria G Siletta; Ausilia Maione; Fernando Alfonso; Peter M Clemmensen; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart Head; Arie Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Joseph Neumann; Dimitri Richter; Patrick Schauerte; Miguel Sousa Uva; David P Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski; Philippe Kolh; Peter Jüni; Peter Juni
Journal:  BMJ       Date:  2014-06-23

10.  Introduction to the Analysis of Survival Data in the Presence of Competing Risks.

Authors:  Peter C Austin; Douglas S Lee; Jason P Fine
Journal:  Circulation       Date:  2016-02-09       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.